US20200023040A1 - Methods of using a gip/glp1 co-agonist for therapy - Google Patents

Methods of using a gip/glp1 co-agonist for therapy Download PDF

Info

Publication number
US20200023040A1
US20200023040A1 US16/518,513 US201916518513A US2020023040A1 US 20200023040 A1 US20200023040 A1 US 20200023040A1 US 201916518513 A US201916518513 A US 201916518513A US 2020023040 A1 US2020023040 A1 US 2020023040A1
Authority
US
United States
Prior art keywords
dose
tirzepatide
weeks
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/518,513
Other languages
English (en)
Inventor
Charles T. BENSON
Axel Haupt
Melissa Kay THOMAS
Shweta URVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US16/518,513 priority Critical patent/US20200023040A1/en
Assigned to ELI LILLY AND COMPANY reassignment ELI LILLY AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BENSON, CHARLES T, HAUPT, AXEL, THOMAS, MELISSA KAY, URVA, SHWETA
Publication of US20200023040A1 publication Critical patent/US20200023040A1/en
Priority to US17/366,453 priority patent/US20210338781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention provides methods of using novel doses of a glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP1) dual agonist peptide, tirzepatide, or a pharmaceutically acceptable salt thereof, to treat type 2 diabetes (T2D). Also, the present invention provides methods of using novel dosing regimens of a GIP/GLP1 dual agonist peptide, tirzepatide, or a pharmaceutically acceptable salt thereof, to treat type 2 diabetes. Furthermore, the present invention provides novel medical uses for tirzepatide, or a pharmaceutically acceptable salt thereof.
  • GIP glucose-dependent insulinotropic polypeptide
  • GLP1 glucagon-like peptide-1
  • the present invention provides a method for treating a condition selected from the group of chronic kidney disease, atherosclerosis, nonalcoholic fatty liver disease (“NAFLD”), and nonalcoholic steatohepatitis (“NASH”).
  • a condition selected from the group of chronic kidney disease, atherosclerosis, nonalcoholic fatty liver disease (“NAFLD”), and nonalcoholic steatohepatitis (“NASH”).
  • NAFLD nonalcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • the present invention provides a method for curing diabetes in certain patients.
  • Diabetes mellitus is a chronic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
  • T2D the combined effects of impaired insulin secretion and insulin resistance are associated with elevated blood glucose levels.
  • U.S. Pat. No. 9,474,780 generally describes compositions containing a GIP/GLP1 co-agonist, administered by parenteral routes, and generally discloses a wide dosage range up to about 30 mg per person per week.
  • U.S. Pat. No. 9,474,780 discloses the use of GIP/GLP1 co-agonists for treating diabetes, obesity, and other conditions.
  • U.S. Pat. No. 9,474,780 describes and claims tirzepatide.
  • GLP1 treatments are associated with nausea, vomiting, and/or diarrhea.
  • GLP-1 receptor agonist dosing regimens significantly increased the incidence of gastrointestinal adverse events. Diabetes Technol Ther. 2015 January; 17(1):35-42.
  • previous clinical trials of a GIP/GLP1 co-agonist compound have been performed and found that tolerability at high doses was limited by gastrointestinal adverse events.
  • Schmitt, C. et al. “Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.” Diabetes Obes. Metab.
  • the present invention provides novel tirzepatide dosing regimens for use in the aforementioned therapies that include a maintenance dose selected from the group consisting of: about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • a maintenance dose selected from the group consisting of: about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides novel dosing regimens that include an escalation dose (i.e., a dose lower than the desired maintenance dose) and a maintenance dose.
  • the present invention provides novel dosing regimens that include one or more escalation doses and one or more maintenance doses.
  • the present invention provides novel dosing regimens that include administering at least one escalation dose about once weekly for a minimum of about four weeks and thereafter at least one maintenance dose about once weekly for a minimum of about four weeks.
  • the doses may be administered for about four weeks. In certain embodiments, the doses may be administered for more than about four weeks as determined by the nurse, patient and/or health care provider. For example, a maintenance dose may be administered for more than about four weeks. In certain embodiments of the present invention a maintenance dose may be increased to the next highest maintenance dose of the present invention if additional glycemic control is needed with or without an intervening escalation dose. For example, in one dosing regimen according to the present invention, the escalation dose is about 2.5 mg and the maintenance dose is about 5.0 mg. In another dosing regimen according to the present invention, two escalation doses are about 2.5 mg and about 7.5 mg and the maintenance doses are about 5.0 mg and 10.0 mg.
  • the escalation doses are about 2.5 mg, about 7.5 mg and about 12.5 mg and the maintenance doses are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • Escalation doses include about 2.5 mg, about 7.5 mg and about 12.5 mg.
  • Maintenance doses include about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • An escalation dose of 2.5 mg may be the initial dose, or starting dose, for the dosing regimen provided herein.
  • the term “escalation” or “escalation dose(s)” means a titration or titration dose, as described herein.
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention is thus a method of treating type 2 diabetes wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein after a first maintenance dose has been administered for the at least about four weeks, a second escalation dose is administered about once weekly for at least about four weeks and thereafter a second maintenance dose is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg and about 7.5 mg and maintenance doses of about 5.0 mg and about 10.0 mg.
  • Another embodiment of the present invention is one where after a second maintenance does has been administered for the at least about four weeks, a third escalation dose is administered about once weekly for at least about four weeks and thereafter a third maintenance does is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg, about 7.5 mg and about 12.5 mg and maintenance doses of about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • a maintenance dose may be increased to a subsequent maintenance dose if additional glycemic control is needed with or without an intervening escalation dose.
  • the present invention further provides a method of treating type 2 diabetes in a patient in need thereof, comprising: administering an escalation dose of about 2.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a second maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a third maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a method treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising: administering at least one escalation dose about once weekly for a minimum of about four weeks and at least one maintenance dose about once weekly for a minimum of about four weeks following the escalation dose; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention is thus a method of improving glycemic control wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein after a first maintenance dose has been administered for the at least about four weeks, a second escalation dose is administered about once weekly for at least about four weeks and thereafter a second maintenance dose is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg and about 7.5 mg and maintenance doses of about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is one where after a second maintenance dose has been administered for the at least about four weeks, a third escalation dose is administered about once weekly for at least about four weeks and thereafter a third maintenance does is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg, about 7.5 mg and about 12.5 mg and maintenance doses of about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • a maintenance dose may be increased to a subsequent maintenance dose if additional glycemic control is needed with or without an intervening escalation dose.
  • the present invention further provides a method of improving glycemic control in a patient in need thereof, comprising: administering an escalation dose of about 2.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a second maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a third maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising:
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of improving glycemic control in a patient in need thereof, comprising:
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of improving glycemic control in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • a method for treating type 2 diabetes in a patient in need thereof comprising: administering tirzepatide, or a pharmaceutically acceptable salt thereof, in a tirzepatide dosing regimen that comprises an initiation phase, at least one escalation phase, and a maintenance phase; wherein the initiation phase comprises administration of 2.5 mg tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for at least about 2 to 4 weeks; wherein the escalation phase comprises administration of a dose that is increased from the initiation phase dose or prior escalation phase dose by about 2.5 mg per week for at least about 2 to 4 weeks per escalation phase, wherein the escalation dose increases by 2.5 mg during each escalation phase until the maintenance phase is reached; and wherein the maintenance phase is about once weekly administration of a dose selected from the group consisting of about 5 mg, about 10 mg and about 15 mg tirzepatide, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of improving weight management in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering at least one maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention is thus a method of improving weight management wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein after a first maintenance dose has been administered for the at least about four weeks, a second escalation dose is administered about once weekly for at least about four weeks and thereafter a second maintenance dose is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg and about 7.5 mg and maintenance doses of about 5.0 mg and about 10.0 mg.
  • Another embodiment of the present invention is one where after a second maintenance does has been administered for the at least about four weeks, a third escalation dose is administered about once weekly for at least about four weeks and thereafter a third maintenance does is administered about once weekly for at least about four weeks.
  • One such method thus includes escalation doses of about 2.5 mg, about 7.5 mg and about 12.5 mg and maintenance doses of about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • a maintenance dose may be increased to a subsequent maintenance dose if additional glycemic control is needed with or without an intervening escalation dose.
  • the present invention further provides a method of improving weight management in a patient in need thereof, comprising: administering an escalation dose of about 2.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a second maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks; and, optionally thereafter, administering a third maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of improving weight management in a patient in need thereof comprising:
  • the present invention provides a method of improving weight management in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of improving weight management in a patient in need thereof, comprising:
  • Another embodiment provides a method of improving weight management in a patient in need thereof, comprising:
  • the present invention provides a method of improving weight management in a patient in need thereof comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of improving weight management in a patient in need thereof, comprising:
  • Another embodiment provides a method of improving weight management in a patient in need thereof, comprising:
  • the present invention provides a method of improving weight management in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of improving weight management in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of improving weight management in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising: administering am escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention for a method of treating chronic kidney disease wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • a method for treating diabetic kidney disease in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a method of treating atherosclerosis in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention for a method of treating atherosclerosis wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides a method of treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention provides a method treating atherosclerosis in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating atherosclerosis in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention provides a method of treating atherosclerosis in a patient in need thereof comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental relative to that escalation dose.
  • An embodiment of the present invention for a method for treating NAFLD wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating NAFLD in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating NAFLD in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising: administering to said patient a dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating NAFLD in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of treating NAFLD in a patient in need thereof comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • a method for treating dyslipidemia in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention for a method of treating NASH wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising:
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating NASH in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating NASH in a patient in need thereof, comprising:
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method of treating NASH in a patient in need thereof, comprising:
  • Another embodiment provides a method of treating NASH in a patient in need thereof, comprising:
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method of treating NASH in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method of treating NASH in a patient in need thereof comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention for a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes wherein the escalation dose administered about once weekly for at least about four weeks is about 2.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 5.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 7.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 10.0 mg.
  • a further embodiment of the present invention is a method wherein the escalation dose administered about once weekly for at least about four weeks is about 12.5 mg and the maintenance dose administered about once weekly for at least about four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered about once weekly for at least about four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered about once weekly for at least about four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a method to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof comprising:
  • the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a method as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament in improving glycemic control in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving glycemic control in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament in improving weight management in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving weight management in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating diabetic kidney disease in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atherosclerosis in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • a method of treating dyslipidemia in a patient in need thereof comprising: administering an escalation dose about once weekly for a minimum of at least about two weeks and thereafter administering a maintenance dose about once weekly for a minimum of at least about two weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof.
  • a method for treating dyslipidemia in a patient in need thereof comprising: administering at least one escalation dose about once weekly for a minimum of about four weeks and at least one maintenance dose about once weekly for a minimum of about four weeks following the escalation dose; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg increment.
  • escalation dose is about 2.5 mg and the maintenance dose is about 5.0 mg.
  • escalation dose is about 7.5 mg and the maintenance dose is about 10.0 mg.
  • escalation dose is about 12.5 mg and the maintenance dose is about 15.0 mg.
  • a method for treating dyslipidemia further comprising an escalation dose of about 7.5 mg and a maintenance dose of about 10.0 mg.
  • a method for treating dyslipidemia further comprising an escalation dose of about 12.5 mg and a maintenance dose of about 15.0 mg.
  • in an embodiment is a method for treating dyslipidemia, wherein the patient in need of such treatment does not have comorbid type 1 or type 2 diabetes.
  • present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NALFD in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NAFLD in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 5.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 10.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • Another embodiment provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising: administering to said patient a maintenance dose of about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, about once weekly for a minimum of about four weeks.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose.
  • the present invention provides a use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to cure diabetes, induce remission or regression of diabetes, or prevent diabetes in a patient in need thereof, comprising:
  • the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 12.5 mg escalation dose. In another aspect, the present invention includes a medicament as described in the preceding paragraph but which does not include administering the 7.5 mg and 12.5 mg escalation doses.
  • An embodiment of the present invention for use in the manufacture of a medicament described above is wherein the escalation dose administered once weekly for four weeks is about 2.5 mg and the maintenance dose administered once weekly for four weeks is about 5.0 mg.
  • a further embodiment of the present invention is wherein the escalation dose administered once weekly for four weeks is about 7.5 mg and the maintenance dose administered once weekly for four weeks is about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation dose administered once weekly for four weeks is about 12.5 mg and the maintenance dose administered once weekly for four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered once weekly for four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered once weekly for four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered once weekly for four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered once weekly for four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • embodiment 1a is the use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for preventing diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about two weeks and thereafter administering maintenance dose about once weekly for a minimum of about two weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • embodiment 2a is the use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for preventing diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about four weeks and thereafter administering a maintenance dose about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof, wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is about a 5.0 mg incremental increase relative to that escalation dose.
  • embodiment 3a is the use of embodiment 1a or 2a, wherein the escalation dose is about 2.5 mg and the maintenance dose is about 5.0 mg.
  • embodiment 4a is the use of embodiment 1a or 2a, wherein the escalation dose is about 7.5 mg and the maintenance dose is about 10.0 mg.
  • embodiment 5a is the use of embodiment 1a or 2a, wherein the escalation dose is about 12.5 mg and the maintenance dose is about 15.0 mg.
  • embodiment 6a is the use of embodiment 3a, further comprising an escalation dose of about 7.5 mg and a maintenance dose of about 10.0 mg.
  • embodiment 7a is the use of embodiment 6a, further comprising an escalation dose of about 12.5 mg and a maintenance dose of a bout 15.0 mg.
  • embodiment 8a is the use of tirzepatide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating chronic kidney disease in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of about two weeks and thereafter administering a maintenance dose about once weekly for a minimum of about two weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is about a 5.0 mg incremental increase relative to that escalation dose.
  • embodiment 10a is the use of embodiment 8a or 9a, wherein the escalation dose is about 2.5 mg and the maintenance dose is about 5.0 mg.
  • embodiment 11a is the use of embodiment 8a or 9a, wherein the escalation dose is about 7.5 mg and the maintenance dose is about 10.0 mg.
  • embodiment 12a is the use of embodiment 8a or 9a, wherein the escalation dose is about 12.5 mg and the maintenance dose is about 15.0 mg.
  • embodiment 13a is the use of embodiment 10a, further comprising an escalation dose of about 7.5 mg and a maintenance dose of about 10.0 mg.
  • embodiment 14a the use of embodiment 13a, further comprising an escalation dose of about 12.5 mg and a maintenance dose of about 15.0 mg.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in improving glycemic control.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in improving glycemic control in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in improving weight management.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in improving weight management in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating chronic kidney disease.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in treating chronic kidney disease in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating atherosclerosis.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in treating atherosclerosis in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating NAFLD.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in treating NAFLD in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in treating NASH.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in treating NASH in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • the present invention provides tirzepatide, or a pharmaceutically acceptable salt thereof, for use in curing diabetes, inducing remission or regression of diabetes, or preventing diabetes.
  • the present invention provides tirzepatride, or a pharmaceutically acceptable salt thereof, for use in curing diabetes, inducing remission or regression of diabetes, or preventing diabetes in a patient in need thereof wherein: an escalation dose is administered about once weekly for a minimum of about four weeks and thereafter a maintenance dose is administered about once weekly for a minimum of about four weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose following an escalation dose is a 2.5 mg incremental increase relative to that escalation dose.
  • An embodiment of the present invention for the uses described above is wherein the escalation dose administered once weekly for four weeks is about 2.5 mg and the maintenance dose administered once weekly for four weeks is about 5.0 mg.
  • a further embodiment of the present invention is wherein the escalation dose administered once weekly for four weeks is about 7.5 mg and the maintenance dose administered once weekly for four weeks is about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation dose administered once weekly for four weeks is about 12.5 mg and the maintenance dose administered once weekly for four weeks is about 15.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered once weekly for four weeks are about 2.5 mg and about 7.5 mg and the maintenance doses administered once weekly for four weeks are about 5.0 mg and about 10.0 mg.
  • a further embodiment of the present invention is wherein the escalation doses administered once weekly for four weeks are about 2.5 mg, about 5.0 mg and about 7.5 mg and the maintenance doses administered once weekly for four weeks are about 5.0 mg, about 10.0 mg and about 15.0 mg.
  • titration dose or “escalation dose” means a dose that is less than the highest desired effective dose for the patient.
  • a “titration dose” or “escalation dose” may become the highest desired effective dose, or “maintenance dose” if such dose is observed to be the desired effective dose for the patient, and such dose may be administered chronically for a period exceeding four weeks.
  • maintenance dose means both a dose that is the highest desired effective dose for the patient, and the maintenance dose may become an escalation dose when such maintenance dose is less than the desired highest effective dose. That is to say, if, for a particular patient, the “about 5 mg” maintenance dose contemplated by the present invention is not the highest desired effective dose, then that 5 mg maintenance dose will become, in retrospect, a titration dose as the particular patient's dose will be increased up until reaching the next highest maintenance dose contemplated by the present invention, e.g., 7.5 mg for at least about 2 weeks to 10 mg for at least about 2 weeks.
  • the invention contemplates that a patient that reaches a maintenance dose of about 10 mg or about 15 mg may, as determined by a physician or other health care provider, need to have their dosage decreased to a lower maintenance dose.
  • tirzepatide for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, a growth differentiation factor 15 modulator (“GDF15”), a peptide tyrosine tyrosine modulator (“PYY”), a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and oxyntomodulin agonist (“OXM”) in the treatment of a condition selected from the group consisting of type 2 diabetes, chronic kidney disease, atherosclerosis, NALFD and NASH.
  • a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM in the improvement of glycemic control and/or weight management.
  • agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM in the improvement of glycemic control and/or weight management.
  • agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM to cure diabetes, induce remission or regression of diabetes,
  • a compound of the present invention is provided in a fixed dose combination with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM.
  • agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM.
  • Nonalcoholic fatty liver disease is a liver disease characterized by an accumulation of fat in the liver of afflicted patients. Patients suffering from NAFLD may consume little or no alcohol, and in an embodiment, the patient does not have comorbid diabetes. NAFLD is a major cause of liver disease worldwide. Younossi et. al. Global epidemiology of nonalcoholic fatty liver disease - Meta - analytic assessment of prevalence, incidence, and outcomes ; Hepatology (July 2016) 64:1; 73-84.
  • Nonalcoholic steatohepatitis is a type of NAFLD with an etiological constellation exhibiting macrovesicular hepatic steatosis, inflammation, hepatocyte ballooning, and fibrosis. NASH may lead to cirrhosis and liver failure. It has been established that patients with NASH are more likely to develop cirrhosis, and have a higher risk of cardiovascular mortality, and hepatocyte carcinoma. This non-alcoholic, non-viral cirrhosis is, in fact, among the top causes of liver transplantation.
  • NAFLD and NASH are progressive diseases characterized by the development of liver fibrosis as NAFLD progresses to NASH.
  • the stage of NASH can be defined, for example, by the NASH CRN (Clinical Research Network).
  • Fibrosis staging measures the amount and pattern of NASH fibrosis, as well as parenchymal architectural remodeling in a patient.
  • NASH is typically diagnosed in a human patient using liver biopsy, and the diagnosis is predicted using MRI-derived proton density fat fraction images (“MRI-PDFF”), plasma cytokeratin 18 (CK18) fragment levels as a biomarker for hepatocyte apoptosis, and plasma Pro-C3 (N-terminal type III collagen propeptide) to predict fibrosis progression, and/or other biomarkers.
  • MRI-PDFF MRI-derived proton density fat fraction images
  • CK18 plasma cytokeratin 18
  • plasma Pro-C3 N-terminal type III collagen propeptide
  • NAFLD Noninvasive biomarkers in NAFLD and NASH—current progress and future promise ; Nature Reviews Gastroenterology & Hepatology; (29 May 2018).
  • NAFLD in which excess lipid deposition occurs in the liver, is typically assessed using imaging methods such as MRI-PDFF.
  • the present invention provides a method for treating NAFLD, comprising administering an effective amount of tirzepatide or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.
  • the present invention provides a method for treating NASH, comprising administering an effective amount of tirzepatide or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.
  • the patient in need of treatment for NASH has comorbid type 2 diabetes.
  • the patient in need of treatment for NASH does not have type 2 diabetes.
  • Chronic kidney disease is defined as abnormalities of kidney structure or function, present for three months, with implications for health of the patient.
  • CKD can be classified on the basis of the glomular filtration rate (“GFR”) into five categories.
  • the GFR can be estimated using biomarkers, including serum creatinine and albumin, albumin to creatinine ratio (“ACR”), and serum cystatin C, Moderate CKD (GFR 30-59 mL/min/1.73 m2) is classified as stage 3 CKD.
  • ACR albumin to creatinine ratio
  • Moderate CKD GFR 30-59 mL/min/1.73 m2
  • CVD cardiovascular disease
  • CV cardiovascular disease
  • the CV mortality in patients with stage 3 and stage four CKD is two-fold and three-fold higher, respectively, when compared with patients with normal renal function.
  • Patients with CKD and established CVD have a much higher mortality rate compared with patients with CVD and normal renal function. Therefore patients with CKD are considered high risk (stage 3 CKD) or very high risk (stage 4-5 CKD or on dialysis).
  • Treatments for patients with CKD typically include diet, exercise, cessation of smoking, antihypertensive medications, and combinations of medications. Desired treatments for CKD reduce inflammation, improve glycemic control, and/or improve cellular function in such patients. There is a desire for additional treatment options for patients with CKD.
  • the present invention provides a method for treating CKD comprising administering an effective amount of tirzepatide to a patient in need thereof.
  • the treatment is for a patient with Stage 3 CKD.
  • the treatment is for a patient having Stage 4 CKD.
  • the treatment is for a patient having Stage 2 CKD.
  • the treatment is for a patient having Stage 1 CKD.
  • Atherosclerosis is a condition that develops when plaque builds up in the walls of the arteries. This buildup narrows the arteries, impeding blood flow. Complications associated with atherosclerosis and the atherosclerosis disease progression may lead to a heart attack or stroke. Despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for people living with diabetes.
  • the present invention provides a method for treating atherosclerosis comprising administering an effective amount of tirzepatide to a patient in need thereof.
  • U.S. Pat. No. 9,474,780 teaches that tirzepatide is useful for the treatment of diabetes, wherein “treating” includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
  • “treating” includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
  • U.S. Pat. No. 9,474,780 teaches that tirzepatide is useful for the treatment of diabetes, wherein “treating” includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
  • “treating” includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
  • This invention provides a cure for diabetes wherein a patient receiving treatment for diabetes using a tirzepatide dosing regimen comprising a 2.5 mg tirzepatide once weekly start dose or escalation dose is administered for four weeks and a 5.0 mg tirzepatide once weekly maintenance dose is administered for at least four weeks; if the patient does not achieve their HbA1c goal, then an escalation dose of about 7.5 mg once weekly is administered for at least four weeks and then a maintenance dose of 10.0 mg tirzepatide once weekly is administered for at least four weeks; wherein, if the patient does not achieve their HbA1c goal from at least 4 weeks treatment using the 10.0 mg once weekly dose, then a 12.5 mg tirzepatide once weekly escalation dose may be administered for at least 4 weeks, followed by a 15 mg once weekly maintenance dose administered until the HbA1C goal is achieved for at least about 2 weeks, and wherein such patient maintains their HbA1c goal after cessation of all medications approved for use in the treatment of diabetes or gly
  • the term “diabetes medication,” “diabetes medicine” and the like means a medication approved by the pertinent regulatory agency for use in the treatment of glycemic control or Type II diabetes.
  • the HbA1c measurement in the patient treated for diabetes is less than or equal to about 5.9%.
  • the patient maintains their HbA1c goal level for at least one month without further tirzepatide administration.
  • the patient previously treated for diabetes using tirzepatide maintains their glycemic goal for at least one month without administration of further tirzepatide or any other diabetes medication.
  • the patient maintains their glycemic goal for at least 6 months without administration of further tirzepatide or any other diabetes medication.
  • the term “diabetes medication,” “diabetes medicine” and the like means a medication approved by the pertinent regulatory agency for use in the treatment of glycemic control or Type II diabetes.
  • the HbA1c measurement in the patient treated for diabetes is less than or equal to about 5.9%.
  • the patient maintains their HbA1c goal level for at least one month without further tirzepatide administration.
  • the patient previously treated for diabetes using tirzepatide maintains their glycemic goal for at least one month without administration of further tirzepatide or any other diabetes medication.
  • the patient maintains their glycemic goal for at least 6 months without administration of further tirzepatide or any other diabetes medication.
  • the doses of the present invention are likely to have specific concentrations of 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL and 30 mg/mL.
  • Such compositions may be presented in a pre-filled syringe. Such pre-filled syringe may be useful for administering one half milliliter of such composition per patient per dose.
  • the doses of the present invention are typically administered subcutaneously.
  • the doses are typically administered using a pre-filled, disposable pen, reusable pen, or automatic pen injector.
  • the device is an automatic injection apparatus as claimed by U.S. Pat. No. 8,734,394.
  • tirzepatide means a GIP/GLP1 dual agonist peptide as described in U.S. Pat. No. 9,474,780 and described by CAS Registry Number: 2023788-19-2. Tirzepatide is described in Example 1 of U.S. Pat. No. 9,474,780, with the following sequence: YX 1 EGTFTSDYSIX 2 LDKIAQKAFVQWLIAGGPSSGAPPPS
  • X 1 is Aib
  • X 2 is Aib
  • K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) 2 -( ⁇ Glu) 1 -CO—(CH 2 ) 18 —CO 2 H
  • the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 1).
  • administering means the administration by a nurse, health care provider, patient or any other individual including self-administration. This includes not only delivering into the body but also prescribing, dispensing or assisting in any way with delivery.
  • the term “increasing the dose”, “increasing the maintenance dose”, “increasing the titration dose” and “increasing the escalation dose” means the raising of the respective dose by a nurse, health care provider, patient or any other individual.
  • “pharmaceutically acceptable salt” is well known to the skilled artisan.
  • a pharmaceutically acceptable salt that is a tirzepatide trifluoroacetate salt.
  • tirzepatide as a non-salt.
  • biomarker means a laboratory measurement that reflects the activity of a disease process. Biomarkers may be used to diagnose a disease or condition, and usually quantitatively correlate (either directly or inversely) with disease progression. In the clinical trial setting, a biomarker is a measure of the effect of a specific treatment that may correlate with an actual clinical endpoint but does not necessarily have a precise relationship; that is, a biomarker is a substitute measure for a clinical endpoint.
  • treatment means to include slowing or attenuating the progression of a disease or disorder.
  • the terms include to alleviate, ameliorate, or reduce one or more symptoms of a disorder or condition, even if the disorder or condition is not eliminated or if the progression is not slowed.
  • cure diabetes means that a patient, using tirzepatide for the treatment of diabetes reaches their glycemic control treatment goal.
  • the tirzepatide treatment to cure diabetes can prevent, reduce the severity of, or induce remission of diabetes in such patient.
  • tirzepatide treatment slows the progression of diabetes in a patient in need of such treatment.
  • a patient using tirzepatide for treatment of diabetes reaches their glycemic control treatment goal, and requires no concomitant diabetes medicine to maintain the glycemic control goal.
  • a patient using tirzepatide in the treatment of diabetes reaches at least their glycemic control treatment goal, and the treatment goal is maintained with cessation of treatment using tirzepatide and all other diabetes medication.
  • a patient using tirzepatide in the treatment of diabetes reaches at least their glycemic control treatment goal, and the treatment goal is maintained for at least a about a month with cessation of treatment using tirzepatide and all other diabetes medications.
  • a patient using tirzepatide in the treatment of diabetes reaches at least their glycemic control treatment goal, and the treatment goal is maintained for at least about six months with cessation of treatment using tirzepatide and all other diabetes medications.
  • the patient is unable to reach their glycemic goals prior to tirzepatide treatment.
  • the patient has failed to reach their glycemic goal using oral diabetes medication.
  • the patient has failed to reach their glycemic goal using metformin treatment.
  • the patient glycemic goal is less than about 5.9% HbA1c.
  • glycemic control refers to the maintenance or reduction of a patient's HbA1c levels; “improving” glycemic control refers to reductions in HbA1c.
  • weight management refers to the management of obesity in an individual; “improving” weight management refers to a reduction in body weight.
  • HbA1c refers to glycated hemoglobin levels, which develop when hemoglobin joins with glucose in the blood. HbA1c levels are a commonly used measure of glycemic control in patients with diabetes, with decreased HbA1c levels generally indicating improved glycemic control. In the context of the methods of the present invention, the methods of the present invention result in a decrease in HbA1c. In certain embodiments, the decrease in HbA1c is decreased relative to the HbA1c levels resulting from treatment with a lower dose of tirzepatide.
  • patient refers to a mammal in need of treatment for a condition or disorder.
  • the patient is a human with a disease or condition that would benefit from treatment with tirzepatide.
  • LOCF last observation carried forward
  • ITT intention to treat
  • composition is prepared substantially as described herein.
  • compositions containing 5, 10, 15, 20, 15, and 30 mg/mL of tirzepatide each contain the ingredients set forth in Table 1. Acid or base is optionally added to attain the desired pH range. Water is added quantum satis (q.s.) to one milliliter total final volume.
  • composition is prepared substantially as described herein.
  • compositions providing 5, 10, 15, 20, 15, and 30 mg/mL compositions of tirzepatide each contain the ingredients set forth in Table 2. Acid or base is optionally added to attain the desired pH range. Water is added quantum satis to one milliliter total final volume.
  • a 6-month (26-week) Phase 2 double-blind clinical study is designed to evaluate the safety, efficacy, and PK/PD of 4 dose levels (1 mg, 5 mg, 10 mg and 15 mg respectively) of tirzepatide once weekly by subcutaneous injection compared with dulaglutide 1.5 mg. once weekly (QW) and placebo QW in patients with T2DM who have inadequate glycemic control with diet and exercise with or without a stable dose of metformin.
  • Tirzepatide dose is up-titrated to the maintenance dose using the following weekly dose increments:
  • Tirzepatide dose Weekly Tirzepatide Dose Increments: 1 mg (LY 1 mg) Week 0-26: 1 mg QW 5 mg (LY 5 mg) Week 0-26: 5 mg QW 10 mg (LY10 mg) Week 0: 5 mg Week 1: 5 mg Week 2-26: 10 mg 15 mg (LY15 mg) Week 0: 5 mg Week 1: 5 mg Week 2: 10 mg Week 3: 10 mg Week 4: 10 mg Week 5: 10 mg Week 6-26: 15 mg
  • efficacy endpoints include the effect of tirzepatide on HbA1c, FBG, body weight, lipids, and waist circumference compared with placebo and with dulaglutide 1.5 mg.
  • the study also evaluates the effect of tirzepatide on GI tolerability, hypoglycemia, hypersensitivity reactions, and pancreatic safety, as well as the development of treatment-emergent anti-drug antibodies. Model-based dose response analyses are performed to predict potential for significant HbA1c lowering and weight loss in longer studies.
  • the primary efficacy outcome of HbA1c change from baseline to the 26-week endpoint is analyzed using a Bayesian dose-response model. Analyses are performed on the intention to treat population (mITT) analysis set. Supportive analysis of the primary efficacy outcome for the mITT dataset are the model for post-baseline measures (MMRM) with body mass index (BMI) ( ⁇ 30 kg/m 2 , ⁇ 30 kg/m 2 ), metformin use, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline HbA1c as a covariate, and patient as a random effect.
  • MMRM body mass index
  • BMI body mass index
  • the percentages of patients with ⁇ 5% or ⁇ 10% body weight loss, reaching the HbA1c target of ⁇ 6.5% or ⁇ 7.0% at 26 weeks, or requiring rescue therapy are analyzed using logistic regression with fixed effects of treatment and strata, and baseline as a covariate.
  • the changes from baseline in FBG (fasting blood glucose), SMBG (self-monitored blood glucose) levels, waist circumference, and mean percentage change in lipids from baseline to 12 and 26 weeks are analyzed using a similar MMRM to the one used for the primary analyses.
  • n number of patients in the population with baseline and post-baseline value at the specified time point.
  • n is the number of patients with events meeting the criteria; N is number of patients in the population; % is percent of patients in treatment group experiencing the event.
  • HbA1c Data % of Patients % of Patients Reaching Reaching HbA1c HbA1c Target Target ⁇ 6% ⁇ 5.7% (odds (odds ratio p-value ratio vs. p-value Endpoint vs. placebo) (vs. pbo) placebo) (vs.
  • the tirzepatide 5 mg, 10 mg, and 15 mg doses significantly decrease fasting serum glucose compared with placebo and dulaglutide 1.5 mg as shown in Table 4.
  • Table 5 summarizes the proportion of patients who attained a weight loss target of ⁇ 5%, ⁇ 10%, and ⁇ 15% at Week 26.
  • the 5 mg, 10 mg, and 15 mg doses of tirzepatide significantly decrease body weight from baseline and are significantly different from placebo.
  • the tirzepatide 5 mg, 10 mg, and 15 mg groups are also significantly different from dulaglutide 1.5 mg
  • Table 6 illustrates the advantageous effect on gastrointestinal adverse event incidence using the methods herein.
  • NCT03131687 the 15 mg dose was associated with higher GI AEs and higher frequency of patients discontinuing study treatment early after relatively short escalation. A 15 mg dose with a more acceptable tolerability profile is desired.
  • Data from NCT03131687 support 15 mg dose as the highest clinically relevant maintenance dose as contemplated by the present invention. Escalation schemes, as claimed herein were investigated to facilitate an acceptably tolerable 15 mg maintenance dosage. See Clinical Study (NCT03311724) immediately below.
  • Tirzepatide dose Group Weekly Tirzepatide Dose Increments: Placebo Week 1-12 Group 1 Weeks 1-2: 2.5 mg Weeks 3-4: 5 mg Weeks 5-8: 10 mg Weeks 9-12: 15 mg Group 2 Weeks 1-4: 2.5 mg Weeks 5-8: 7.5 mg Weeks 9-12: 15 mg Group 3 Weeks 1-4: 4 mg Weeks: 5-8: 8 mg Weeks 9-12: 12 mg
  • Clinically relevant biomarkers are measured in clinical studies to further support the use of tirzepatide for treating chronic kidney disease. In study NCT03131687, no decrease in eGFR was observed at any dosage. Clinical study laboratory measurements support the use of tirzepatide in the treatment of chronic kidney disease. Clinically relevant biomarkers are measured to assess and support the use of tirzepatide in the treatment of atherosclerosis. Clinically relevant triglyceride levels decrease in all tirzepatide treatment groups. Clinical observations support that tirezepatide can be beneficial for use in the treatment of atherosclerosis.
  • Biomarkers predictive of NAFLD are observed during clinical studies to demonstrate the beneficial effect of tirzepatide in the treatment of NAFLD.
  • Biomarkers predictive of NASH are observed during clinical studies to demonstrate the beneficial effect of tirzepatide in the treatment of NAFLD.
  • HbA1c levels in tirzepatide treated patients reaching their glycemic control goals, and ceasing the use of diabetes medications, are measured during follow up to validate a diabetes cure in such patients.
  • a clinical trial studying the three maintenance doses of the present invention (5.0 mg, 10.0 mg and 15.0 mg) in the dosing regimens of the present invention is conducted as follows.
  • the starting dose of tirzepatide is 2.5 mg once weekly for 4 weeks, followed by an increase to 5 mg once weekly, for the duration of the study low-dose arm.
  • the starting dose of tirzepatide is 2.5 mg once weekly for 4 weeks, then the dose is increased by 2.5 mg every 4 weeks (5 mg once weekly for 4 weeks then 7.5 once weekly for four weeks) until the 10-mg dose is reached and maintained for the duration of the study.
  • the starting dose of tirzepatide will be 2.5 mg once weekly for 4 weeks, then the dose will be increased by 2.5 mg every 4 weeks (5 mg once weekly for four weeks then 7.5 mg once weekly for four weeks then 10 mg once weekly for four weeks then 12.5 mg once weekly for four weeks) until the 15-mg tirzepatide dose is reached and maintained for the duration of the study.
  • the maintenance dose may be decreased to 10 mg.
  • X 1 is Aib
  • X 2 is Aib
  • K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) 2 -( ⁇ Glu) 1 -CO—(CH 2 ) 18 —CO 2 H
  • the C-terminal amino acid is amidated as a C-terminal primary amide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US16/518,513 2018-07-23 2019-07-22 Methods of using a gip/glp1 co-agonist for therapy Abandoned US20200023040A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/518,513 US20200023040A1 (en) 2018-07-23 2019-07-22 Methods of using a gip/glp1 co-agonist for therapy
US17/366,453 US20210338781A1 (en) 2018-07-23 2021-07-02 Methods of using a gip/glp1 co-agonist for therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862702061P 2018-07-23 2018-07-23
US201862730565P 2018-09-13 2018-09-13
US201862740619P 2018-10-03 2018-10-03
US16/518,513 US20200023040A1 (en) 2018-07-23 2019-07-22 Methods of using a gip/glp1 co-agonist for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/366,453 Division US20210338781A1 (en) 2018-07-23 2021-07-02 Methods of using a gip/glp1 co-agonist for therapy

Publications (1)

Publication Number Publication Date
US20200023040A1 true US20200023040A1 (en) 2020-01-23

Family

ID=68387389

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/518,513 Abandoned US20200023040A1 (en) 2018-07-23 2019-07-22 Methods of using a gip/glp1 co-agonist for therapy
US17/366,453 Pending US20210338781A1 (en) 2018-07-23 2021-07-02 Methods of using a gip/glp1 co-agonist for therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/366,453 Pending US20210338781A1 (en) 2018-07-23 2021-07-02 Methods of using a gip/glp1 co-agonist for therapy

Country Status (13)

Country Link
US (2) US20200023040A1 (fr)
EP (1) EP3826716A1 (fr)
JP (2) JP2021533094A (fr)
KR (1) KR20210024583A (fr)
CN (1) CN112512633A (fr)
AU (2) AU2019309796B2 (fr)
BR (1) BR112020026372A2 (fr)
CA (1) CA3107344A1 (fr)
IL (1) IL280258A (fr)
MA (1) MA53390A (fr)
MX (1) MX2021000794A (fr)
SG (1) SG11202100112YA (fr)
WO (1) WO2020023382A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320683A (zh) * 2019-09-25 2020-06-23 成都奥达生物科技有限公司 一种替瑞帕肽类似物
WO2021154593A1 (fr) * 2020-01-30 2021-08-05 Eli Lilly And Company Utilisations thérapeutiques de tirzépatide
WO2022159395A1 (fr) * 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
WO2022271611A1 (fr) * 2021-06-25 2022-12-29 Eli Lilly And Company Méthodes de traitement de l'apnée obstructive du sommeil
US11779648B2 (en) 2020-07-22 2023-10-10 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US11840560B2 (en) 2022-01-20 2023-12-12 Novo Nordisk A/S Prodrugs and uses thereof
WO2024006662A1 (fr) * 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
WO2023141044A1 (fr) * 2022-01-18 2023-07-27 Viking Therapeutics, Inc. Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
WO2024059480A2 (fr) * 2022-09-12 2024-03-21 Eli Lilly And Company Gip/glp1 destiné à être utilisé en thérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117742C2 (uk) 2010-03-01 2018-09-25 Елі Ліллі Енд Компані Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320683A (zh) * 2019-09-25 2020-06-23 成都奥达生物科技有限公司 一种替瑞帕肽类似物
WO2021154593A1 (fr) * 2020-01-30 2021-08-05 Eli Lilly And Company Utilisations thérapeutiques de tirzépatide
JP2023513076A (ja) * 2020-01-30 2023-03-30 イーライ リリー アンド カンパニー チルゼパチドの治療的使用
EP4096703A4 (fr) * 2020-01-30 2024-02-28 Lilly Co Eli Utilisations thérapeutiques de tirzépatide
US11779648B2 (en) 2020-07-22 2023-10-10 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
WO2022159395A1 (fr) * 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
US11744873B2 (en) 2021-01-20 2023-09-05 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022210988B2 (en) * 2021-01-20 2023-11-16 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022210988B9 (en) * 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022271611A1 (fr) * 2021-06-25 2022-12-29 Eli Lilly And Company Méthodes de traitement de l'apnée obstructive du sommeil
US11840560B2 (en) 2022-01-20 2023-12-12 Novo Nordisk A/S Prodrugs and uses thereof
WO2024006662A1 (fr) * 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation

Also Published As

Publication number Publication date
KR20210024583A (ko) 2021-03-05
BR112020026372A2 (pt) 2021-03-23
CN112512633A (zh) 2021-03-16
AU2019309796A1 (en) 2021-01-21
TW202019460A (zh) 2020-06-01
SG11202100112YA (en) 2021-02-25
CA3107344A1 (fr) 2020-01-30
JP2021533094A (ja) 2021-12-02
JP2022130686A (ja) 2022-09-06
MX2021000794A (es) 2021-04-12
EP3826716A1 (fr) 2021-06-02
US20210338781A1 (en) 2021-11-04
MA53390A (fr) 2021-06-02
AU2022291585A1 (en) 2023-02-02
AU2019309796B2 (en) 2022-10-13
IL280258A (en) 2021-03-01
WO2020023382A1 (fr) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2019309796B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
Yamada et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Wilcox et al. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar
Mann et al. Liraglutide and renal outcomes in type 2 diabetes
Betônico et al. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control
Weinstock et al. Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
Davies et al. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
Haneda et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus
Dicker DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors
Yang et al. Therapeutic application of GPR119 ligands in metabolic disorders
Guja et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
Reilhac et al. Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
EP2329848B1 (fr) Lixisénatide en tant que traitement d'appoint à l'insuline glargine et à la metformine dans le diabète de type 2
Terauchi et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
Gallwitz et al. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Shestakova et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
TW201639551A (zh) 小兒第２型糖尿病病患之治療
Ahrén Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
TWI842722B (zh) 使用gip/glp1共促效劑之療法
US20140378374A1 (en) Methods of treatment
US20210100872A1 (en) Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus
Goldenberg et al. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Cases Glucagon-like peptide 1 (GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist
Gami et al. New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
WO2024059480A2 (fr) Gip/glp1 destiné à être utilisé en thérapie

Legal Events

Date Code Title Description
AS Assignment

Owner name: ELI LILLY AND COMPANY, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENSON, CHARLES T;HAUPT, AXEL;THOMAS, MELISSA KAY;AND OTHERS;SIGNING DATES FROM 20190712 TO 20190715;REEL/FRAME:049822/0899

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION